Delcath Systems Inc (NAS:DCTH)
$ 11.22 0.57 (5.35%) Market Cap: 358.75 Mil Enterprise Value: 347.82 Mil PE Ratio: 0 PB Ratio: 36.67 GF Score: 66/100

Delcath Systems Inc Call with Dr. Jonathan Zager, Principal Investigator for Delcath's Ph3 FOCUS Study Transcript

Sep 30, 2020 / 07:00PM GMT
Release Date Price: $11.61 (+3.85%)
Operator

Good morning, ladies and gentlemen. Welcome to the Encode Ideas, L.P. key opinion leader call with Dr. Jonathan Zager, Principal Investigator for Delcath's Phase 3 FOCUS study. As a reminder, this conference call is being recorded. I would now like to turn the meeting over to Hogan Mullally, Partner, Encode Ideas.

Hogan Mullally
Encode Ideas, L.P. - Analyst

Thank you, and welcome, everyone, to the call. We really appreciate you participating. My name is Hogan Mullally. I am a Partner at Encode Ideas. I'm pleased to be joined on this call by Dr. Jonathan Zager, Chief Academic Officer and a surgical oncologist and senior member of the Department of Cutaneous Oncology and Sarcoma at Moffitt Cancer Center.

Dr. Zager is also the principal investigator in the pivotal Phase 3 FOCUS study investigating melphalan hepatic delivery system via percutaneous hepatic perfusion or as we'll refer to it throughout the call PHP in the treatment of metastatic ocular melanoma.

Before we begin our discussion on metastatic ocular melanoma and PHP, I'd like to run

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot